In December 2019, the first case of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) was described and by March 2020, the World Health Organization had declared the disease (Coronavirus disease 2019, COVID-19) a pandemic. Whilst respiratory symptoms are the fundamental feature of the disease, evidence indicates that the disease is associated with coagulation dysfunction which predisposes patients to an increased risk of both venous and arterial thromboembolism (TE) and potentially increased mortality risk as a consequence. Biomarkers associated with TE (D-dimers) are often raised in people with COVID but without clear evidence of TE. It is important to understand who is at most risk of TE, to manage disease effectively. This dataset (in OMOP) describes patients with and without COVID who were admitted to UHB including all those with and without TE.

PIONEER geography The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix. Birmingham was hard hit by all COVID waves and University Hospitals Birmingham NHS Foundation Trust (UHB) had >8000 COVID admissions by the end of December 2020.

EHR. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & an expanded 250 ITU bed capacity during COVID. UHB runs a fully electronic healthcare record (EHR) (PICS Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Scope: All patients admitted during the first wave of the COVID-19, both with and without COVID. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to acute care process (timings, staff grades, specialty review, wards), presenting complaint, SARS-CoV-2 swab result, diagnosis of TE, clotting parameters, D-Dimers, acuity, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations), all blood results, imaging reports, all prescribed & administered treatments (fluids, antibiotics, inotropes, vasopressors, organ support), all outcomes.

Available supplementary data: Matched controls ambulance, synthetic data.

Available supplementary support: Analytics, Model build, validation & refinement A.I. Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.